| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tigecycline | CTRPv2 | pan-cancer | AAC | 0.046 | 0.4 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.035 | 0.4 |
| mRNA | BRD8899 | CTRPv2 | pan-cancer | AAC | -0.035 | 0.4 |
| mRNA | BRD4132 | CTRPv2 | pan-cancer | AAC | -0.035 | 0.4 |
| mRNA | BRD-K34099515 | CTRPv2 | pan-cancer | AAC | -0.071 | 0.4 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | 0.034 | 0.4 |
| mRNA | PHA-665752 | CCLE | pan-cancer | AAC | 0.044 | 0.4 |
| mRNA | Vorinostat | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | neopeltolide | CTRPv2 | pan-cancer | AAC | -0.066 | 0.4 |
| mRNA | pifithrin-mu | CTRPv2 | pan-cancer | AAC | -0.032 | 0.4 |